Neuronal nicotinic acetylcholine receptor alpha-3-alpha-5-beta-4 (α3α5β4 nAChR)

The neuronal nicotinic acetylcholine receptor alpha-3-alpha-5-beta-4 (α3α5β4) is a pentameric ligand-gated ion channel composed of α3, α5, and β4 subunits (UniProt: P32297, P30532, P43681). This specific subtype is predominantly expressed in the autonomic ganglia and the medial habenula-interpeduncular nucleus (MHb-IPN) pathway of the central nervous system (PubMed: 20610761). It plays a critical role in mediating fast excitatory synaptic transmission and regulating the release of various neurotransmitters, particularly in the context of the brain's reward and aversion circuits. Genetic variations within the CHRNA5-CHRNA3-CHRNB4 gene cluster, such as the rs16969968 polymorphism, are strongly associated with an increased risk of nicotine dependence, lung cancer, and peripheral arterial disease (PubMed: 18391952). The α5 subunit acts as a crucial modulator of the receptor's calcium permeability and desensitization rates; its presence in the MHb-IPN pathway is essential for signaling the aversive effects of high-dose nicotine. Pharmacological targeting of this receptor is primarily focused on smoking cessation, with drugs like varenicline and cytisine acting as partial agonists. However, therapeutic development is challenged by the receptor's widespread presence in the autonomic nervous system, which can lead to significant cardiovascular and gastrointestinal side effects.

Other names

CHRNA3-CHRNA5-CHRNB4 complexalpha3-alpha5-beta4 nicotinic receptorGanglionic-type nicotinic receptorCHRNA3/A5/B4

Ligand-gated ion channel modulation; agonists and partial agonists trigger cation influx (primarily Na+ and Ca2+) leading to membrane depolarization, while antagonists block channel activity (PubMed: 20610761).